IL4I1 inhibitors and methods of use
Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.
1. A compound, or a pharmaceutically acceptable salt thereof, having the Formula Ia
wherein,
A is aryl;
L is a straight or branched (C 1 -C 5 ) alkylenyl, wherein one or more —CH 2 — groups in L are optionally and independently replaced with a moiety selected from the group consisting of O, and NH;
each occurrence of R 1 is independently halogen, C 1 -C 6 alkyl, or cycloheteroalkyl;
each occurrence of R 2 is independently
R 3 is hydrogen, C 1 -C 6 alkyl or haloC 1 -C 6 alkyl;
m is 0, 1 or 2; and
n is 1, 2 or 3.
2. The compound of claim 1 , or pharmaceutically acceptable salt thereof, wherein L is —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 CH 2 —, —CH 2 CH 2 CH 2 O—, or —CHCH 3 —.
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is phenyl.
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 0.
5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 1 or 2 and R 1 is fluorine, chlorine, pyrrolidine, methyl or ethyl.
6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is hydrogen, methyl or difluoromethyl.
7. A method of treating cancer comprising administering to a patient in need thereof a compound of claim 1 or a pharmaceutically acceptable salt thereof.
8. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
9. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
10. A compound having the following structure
11. A compound having the following structure
or a pharmaceutically acceptable salt thereof.
12. A method of treating cancer comprising administering to a patient in need thereof a compound of claim 11 , or pharmaceutically acceptable salt thereof.
13. A pharmaceutical composition comprising a compound of claim 11 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
14. A pharmaceutical composition comprising a compound of claim 10 and a pharmaceutically acceptable carrier.
15. A compound having the following structure
16. A compound having the following structure
or a pharmaceutically acceptable salt thereof.
17. A method of treating cancer comprising administering to a patient in need thereof a compound of claim 16 , or pharmaceutically acceptable salt thereof.
18. A pharmaceutical composition comprising a compound of claim 16 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
19. A pharmaceutical composition comprising a compound of claim 15 and a pharmaceutically acceptable carrier.
20. A compound having the following structure
21. A compound having the following structure
or a pharmaceutically acceptable salt thereof.
22. A method of treating cancer comprising administering to a patient in need thereof a compound of claim 21 , or pharmaceutically acceptable salt thereof.
23. A pharmaceutical composition comprising a compound of claim 21 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
24. A pharmaceutical composition comprising a compound of claim 20 and a pharmaceutically acceptable carrier.
25. A compound selected from: